{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:46:49Z","timestamp":1776872809487,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00403-019-01986-x","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T20:02:25Z","timestamp":1571083345000},"page":"93-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Antibodies towards high-density lipoprotein components in patients with psoriasis"],"prefix":"10.1007","volume":"312","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-2734","authenticated-orcid":false,"given":"Maria Joao","family":"Paiva-Lopes","sequence":"first","affiliation":[]},{"given":"Joana R.","family":"Batuca","sequence":"additional","affiliation":[]},{"given":"Sofia","family":"Gouveia","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Ana Luisa","family":"Papoila","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Delgado","family":"Alves","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"key":"1986_CR1","first-page":"2","volume":"33","author":"W Alwan","year":"2015","unstructured":"Alwan W, Nestle FO (2015) Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol 33:2\u20136","journal-title":"Clin Exp Rheumatol"},{"key":"1986_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2012","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM (2012) Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133:377\u2013385. \nhttps:\/\/doi.org\/10.1038\/jid.2012.339","journal-title":"J Invest Dermatol"},{"key":"1986_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/jamadermatol.2014.2094","volume":"151","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Wang S, Shin DB et al (2015) Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol 151:161\u2013169. \nhttps:\/\/doi.org\/10.1001\/jamadermatol.2014.2094","journal-title":"JAMA Dermatol"},{"key":"1986_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/HJH.0b013e32835bcce1","volume":"31","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ (2013) The association between psoriasis and hypertension. J Hypertens 31:433\u2013443. \nhttps:\/\/doi.org\/10.1097\/HJH.0b013e32835bcce1","journal-title":"J Hypertens"},{"key":"1986_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann AL, Shin DB, Wang X et al (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829\u2013835. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2006.08.040","journal-title":"J Am Acad Dermatol"},{"key":"1986_CR6","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/nutd.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ (2012) The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2:e54. \nhttps:\/\/doi.org\/10.1038\/nutd.2012.26","journal-title":"Nutr Diabetes"},{"key":"1986_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/2013.jamadermatol.406","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ (2013) Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 149:84\u201391. \nhttps:\/\/doi.org\/10.1001\/2013.jamadermatol.406","journal-title":"JAMA Dermatol"},{"key":"1986_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/bjd.12101","volume":"168","author":"C Ma","year":"2013","unstructured":"Ma C, Harskamp CT, Armstrong EJ, Armstrong AW (2013) The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 168:486\u2013495. \nhttps:\/\/doi.org\/10.1111\/bjd.12101","journal-title":"Br J Dermatol"},{"key":"1986_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jaad.2005.11.1079","volume":"54","author":"L Mallbris","year":"2006","unstructured":"Mallbris L, Granath F, Hamsten A, St\u00e5hle M (2006) Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 54:614\u2013621. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2005.11.1079","journal-title":"J Am Acad Dermatol"},{"key":"1986_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.113.000062","volume":"2","author":"EJ Armstrong","year":"2013","unstructured":"Armstrong EJ, Harskamp CT, Armstrong AW (2013) Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2:1\u201310. \nhttps:\/\/doi.org\/10.1161\/JAHA.113.000062","journal-title":"J Am Heart Assoc"},{"key":"1986_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12490","author":"IM Miller","year":"2013","unstructured":"Miller IM, Skaaby T, Ellervik C, Jemec GB (2013) Quantifying cardiovascular disease risk factors in psoriasis patients\u2014a meta-analysis. Br J Dermatol. \nhttps:\/\/doi.org\/10.1111\/bjd.12490","journal-title":"Br J Dermatol"},{"key":"1986_CR12","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1038\/jid.2013.149","volume":"133","author":"EJ Samarasekera","year":"2013","unstructured":"Samarasekera EJ, Neilson JM, Warren RB et al (2013) Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 133:2340\u20132346. \nhttps:\/\/doi.org\/10.1038\/jid.2013.149","journal-title":"J Invest Dermatol"},{"key":"1986_CR13","doi-asserted-by":"publisher","first-page":"775.e1","DOI":"10.1016\/j.amjmed.2011.03.028","volume":"124","author":"NN Mehta","year":"2011","unstructured":"Mehta NN, Yu Y, Pinnelas R et al (2011) Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 124:775.e1\u20136. \nhttps:\/\/doi.org\/10.1016\/j.amjmed.2011.03.028","journal-title":"Am J Med"},{"key":"1986_CR14","doi-asserted-by":"publisher","first-page":"H867","DOI":"10.1152\/ajpheart.00774.2016","volume":"312","author":"CL Harrington","year":"2017","unstructured":"Harrington CL, Dey AK, Yunus R et al (2017) Psoriasis as a human model of disease to study inflammatory atherogenesis. Am J Physiol Heart Circ Physiol 312:H867\u2013H873. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00774.2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1986_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-017-0382-4","author":"MJ Paiva-Lopes","year":"2017","unstructured":"Paiva-Lopes MJ, Delgado Alves J (2017) Psoriasis-associated vascular disease: the role of HDL. J Biomed Sci. \nhttps:\/\/doi.org\/10.1186\/s12929-017-0382-4","journal-title":"J Biomed Sci"},{"key":"1986_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/emmm.201200224","volume":"4","author":"C Besler","year":"2012","unstructured":"Besler C, L\u00fcscher TF, Landmesser U (2012) Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 4:251\u2013268. \nhttps:\/\/doi.org\/10.1002\/emmm.201200224","journal-title":"EMBO Mol Med"},{"key":"1986_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","volume":"128","author":"RS Rosenson","year":"2013","unstructured":"Rosenson RS, Brewer HB, Ansell B et al (2013) Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 128:1256\u20131267. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.000962","journal-title":"Circulation"},{"key":"1986_CR18","doi-asserted-by":"publisher","DOI":"10.5772\/67141","author":"R White","year":"2017","unstructured":"White R, Giordano S, Datta G (2017) Role of HDL-associated proteins and lipids in the regulation of inflammation. Adv Lipoprotein Res. \nhttps:\/\/doi.org\/10.5772\/67141","journal-title":"Adv Lipoprotein Res"},{"key":"1986_CR19","doi-asserted-by":"publisher","first-page":"949072","DOI":"10.1155\/2011\/949072","volume":"2011","author":"H Zhang","year":"2011","unstructured":"Zhang H, Wu LM, Wu J (2011) Cross-talk between apolipoprotein e and cytokines. Mediators Inflamm 2011:949072. \nhttps:\/\/doi.org\/10.1155\/2011\/949072","journal-title":"Mediators Inflamm"},{"key":"1986_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIRCRESAHA.117.305844","volume":"117","author":"K Li","year":"2015","unstructured":"Li K, Ching D, Luk FS, Raffai RL (2015) Apolipoprotein e enhances MicroRNA-146a in monocytes and macrophages to suppress nuclear factor-kB-driven inflammation and atherosclerosis. Circ Res 117:e1\u2013e11. \nhttps:\/\/doi.org\/10.1161\/CIRCRESAHA.117.305844","journal-title":"Circ Res"},{"key":"1986_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2009.05.034","volume":"208","author":"EM Tsompanidi","year":"2010","unstructured":"Tsompanidi EM, Brinkmeier MS, Fotiadou EH et al (2010) HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 208:3\u20139. \nhttps:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.05.034","journal-title":"Atherosclerosis"},{"key":"1986_CR22","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/art.10542","volume":"46","author":"J Delgado Alves","year":"2002","unstructured":"Delgado Alves J, Ames PRJ, Donohue S et al (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthr Rheum 46:2686\u20132694. \nhttps:\/\/doi.org\/10.1002\/art.10542","journal-title":"Arthr Rheum"},{"key":"1986_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1196\/annals.1422.016","volume":"1108","author":"JR Batuca","year":"2007","unstructured":"Batuca JR, Ames PRJ, Isenberg DA, Delgado Alves J (2007) Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci 1108:137\u2013146. \nhttps:\/\/doi.org\/10.1196\/annals.1422.016","journal-title":"Ann N Y Acad Sci"},{"key":"1986_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/rheumatology\/ken397","volume":"48","author":"JR Batuca","year":"2009","unstructured":"Batuca JR, Ames PRJ, Amaral M et al (2009) Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology 48:26\u201331. \nhttps:\/\/doi.org\/10.1093\/rheumatology\/ken397","journal-title":"Rheumatology"},{"key":"1986_CR25","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/0961203309357765","volume":"19","author":"PRJ Ames","year":"2010","unstructured":"Ames PRJ, Matsuura E, Batuca JR et al (2010) High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. Lupus 19:711\u2013716. \nhttps:\/\/doi.org\/10.1177\/0961203309357765","journal-title":"Lupus"},{"key":"1986_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/art.27298","volume":"62","author":"BH Hahn","year":"2010","unstructured":"Hahn BH (2010) Should antibodies to high-density lipoprotein cholesterol and its components be measured in all systemic lupus erythematosus patients to predict risk of atherosclerosis? Arthr Rheum 62:639\u2013642. \nhttps:\/\/doi.org\/10.1002\/art.27298","journal-title":"Arthr Rheum"},{"key":"1986_CR27","first-page":"1126","volume":"35","author":"HW Eckerson","year":"1983","unstructured":"Eckerson HW, Wyte CM, La Du BN (1983) The human serum paraoxonase\/arylesterase polymorphism. Am J Hum Genet 35:1126\u20131138","journal-title":"Am J Hum Genet"},{"key":"1986_CR28","doi-asserted-by":"publisher","first-page":"295705","DOI":"10.4061\/2011\/295705","volume":"2011","author":"E Profumo","year":"2011","unstructured":"Profumo E, Buttari B, Rigan\u00f2 R (2011) Oxidative stress in cardiovascular inflammation: its involvement in autoimmune responses. Int J Inflam 2011:295705. \nhttps:\/\/doi.org\/10.4061\/2011\/295705","journal-title":"Int J Inflam"},{"key":"1986_CR29","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jdiacomp.2016.02.014","volume":"30","author":"D El-Lebedy","year":"2016","unstructured":"El-Lebedy D, Rasheed E, Kafoury M et al (2016) Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus. J Diabetes Complicat 30:580\u2013585. \nhttps:\/\/doi.org\/10.1016\/j.jdiacomp.2016.02.014","journal-title":"J Diabetes Complicat"},{"key":"1986_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4414\/smw.2013.13781","volume":"143","author":"N Vuilleumier","year":"2013","unstructured":"Vuilleumier N, Dayer JM, Von Eckardstein A, Roux-Lombard P (2013) Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins? Swiss Med Wkly 143:1\u201312. \nhttps:\/\/doi.org\/10.4414\/smw.2013.13781","journal-title":"Swiss Med Wkly"},{"key":"1986_CR31","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1021\/acs.biochem.6b00389","volume":"55","author":"S Filou","year":"2016","unstructured":"Filou S, Lhomme M, Karavia EA et al (2016) Distinct roles of apolipoproteins A1 and e in the modulation of high-density lipoprotein composition and function. Biochemistry 55:3752\u20133762. \nhttps:\/\/doi.org\/10.1021\/acs.biochem.6b00389","journal-title":"Biochemistry"},{"key":"1986_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/868251","author":"PC Teixeira","year":"2012","unstructured":"Teixeira PC, Cutler P, Vuilleumier N (2012) Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives. Clin Dev Immunol. \nhttps:\/\/doi.org\/10.1155\/2012\/868251","journal-title":"Clin Dev Immunol"},{"key":"1986_CR33","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4330\/wjc.v6.i5.314","volume":"6","author":"N Vuilleumier","year":"2014","unstructured":"Vuilleumier N, Montecucco F, Hartley O (2014) Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World J Cardiol 6:314\u2013326. \nhttps:\/\/doi.org\/10.4330\/wjc.v6.i5.314","journal-title":"World J Cardiol"},{"key":"1986_CR34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/labinvest.2016.56","volume":"96","author":"DA Chistiakov","year":"2016","unstructured":"Chistiakov DA, Orekhov AN, Bobryshev YV (2016) ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease. Lab Invest 96:708\u2013718. \nhttps:\/\/doi.org\/10.1038\/labinvest.2016.56","journal-title":"Lab Invest"},{"key":"1986_CR35","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1042\/CS20160374","volume":"130","author":"J Rodriguez-Carrio","year":"2016","unstructured":"Rodriguez-Carrio J, Alperi-Lopez M, Lopez-Mejias R et al (2016) Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis. Clin Sci 130:1889\u20131899. \nhttps:\/\/doi.org\/10.1042\/CS20160374","journal-title":"Clin Sci"},{"key":"1986_CR36","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1194\/jlr.M027367","volume":"53","author":"M Holzer","year":"2012","unstructured":"Holzer M, Wolf P, Curcic S et al (2012) Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 53:1618\u20131624. \nhttps:\/\/doi.org\/10.1194\/jlr.M027367","journal-title":"J Lipid Res"},{"key":"1986_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/535612","author":"A Pietrzak","year":"2010","unstructured":"Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC (2010) Lipid disturbances in psoriasis: an update. Mediators Inflamm. \nhttps:\/\/doi.org\/10.1155\/2010\/535612","journal-title":"Mediators Inflamm"},{"key":"1986_CR38","first-page":"S277","volume":"54","author":"JR Batuca","year":"2011","unstructured":"Batuca JR et al (2011) Antibodies towards HDL components in type 2 diabetes patients are associated with modifications in the anti-atherogenic propertiesof HDL. Diabetologia 54:S277\u2013S278","journal-title":"Diabetologia"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-019-01986-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-019-01986-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-019-01986-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T23:04:16Z","timestamp":1602543856000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-019-01986-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1986"],"URL":"https:\/\/doi.org\/10.1007\/s00403-019-01986-x","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,14]]},"assertion":[{"value":"13 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}